PURPOSE: We assessed the impact of hexaminolevulinate fluorescence cystoscopic detection of papillary, nonmuscle invasive bladder cancer on the long-term recurrence rate. MATERIALS AND METHODS: Long-term followup was assessed in 551 participants enrolled in a prospective, randomized study of fluorescence cystoscopyfor Ta or T1 urothelial bladder cancer. In the original study 280 patients in the white light cystoscopy group and 271 in thefluorescence cystoscopy group were followed with cystoscopy for 3, 6 and 9 months after initial resection or until recurrence. A study extension protocol was done for long-term followup of these patients. RESULTS: Followup information was obtained for 261 of the 280 patients (93%) in the white light group and 255 of the 271 (94%) in the fluorescence group. Median followup in the white light and fluorescence groups was 53.0 and 55.1 months, and 83 (31.8%) and 97 patients (38%) remained tumor free, respectively. Median time to recurrence was 9.4 months in the white light group and 16.4 months in the fluorescence group (p = 0.04). The intravesical therapy rate was similar in the 2 groups (46% and 45%, respectively). Cystectomy was done in 22 of 280 cases (7.9%) in the white light group and in 13 of the 271 (4.8%) in the fluorescence group (p = 0.16). CONCLUSIONS:Hexaminolevulinate fluorescence cystoscopy significantly improves long-term bladder cancer time to recurrence with a trend toward improved bladder preservation.
RCT Entities:
PURPOSE: We assessed the impact of hexaminolevulinate fluorescence cystoscopic detection of papillary, nonmuscle invasive bladder cancer on the long-term recurrence rate. MATERIALS AND METHODS: Long-term followup was assessed in 551 participants enrolled in a prospective, randomized study of fluorescence cystoscopy for Ta or T1 urothelial bladder cancer. In the original study 280 patients in the white light cystoscopy group and 271 in the fluorescence cystoscopy group were followed with cystoscopy for 3, 6 and 9 months after initial resection or until recurrence. A study extension protocol was done for long-term followup of these patients. RESULTS: Followup information was obtained for 261 of the 280 patients (93%) in the white light group and 255 of the 271 (94%) in the fluorescence group. Median followup in the white light and fluorescence groups was 53.0 and 55.1 months, and 83 (31.8%) and 97 patients (38%) remained tumor free, respectively. Median time to recurrence was 9.4 months in the white light group and 16.4 months in the fluorescence group (p = 0.04). The intravesical therapy rate was similar in the 2 groups (46% and 45%, respectively). Cystectomy was done in 22 of 280 cases (7.9%) in the white light group and in 13 of the 271 (4.8%) in the fluorescence group (p = 0.16). CONCLUSIONS:Hexaminolevulinate fluorescence cystoscopy significantly improves long-term bladder cancer time to recurrence with a trend toward improved bladder preservation.
Authors: Dmitry I Daniltchenko; Claus R Riedl; Markus D Sachs; Frank Koenig; Kurosch L Daha; Heinz Pflueger; Stefan A Loening; Dietmar Schnorr Journal: J Urol Date: 2005-12 Impact factor: 7.450
Authors: Arnulf Stenzl; Maximilian Burger; Yves Fradet; Lance A Mynderse; Mark S Soloway; J Alfred Witjes; Martin Kriegmair; Alexander Karl; Yu Shen; H Barton Grossman Journal: J Urol Date: 2010-09-17 Impact factor: 7.450
Authors: Yves Fradet; H Barton Grossman; Leonard Gomella; Seth Lerner; Michael Cookson; David Albala; Michael J Droller Journal: J Urol Date: 2007-05-11 Impact factor: 7.450
Authors: Stefan Denzinger; Maximilian Burger; Bernhard Walter; Ruth Knuechel; Wolfgang Roessler; Wolf F Wieland; Thomas Filbeck Journal: Urology Date: 2007-04 Impact factor: 2.649
Authors: Martin C Schumacher; Sten Holmäng; Thomas Davidsson; Bengt Friedrich; Jörgen Pedersen; N Peter Wiklund Journal: Eur Urol Date: 2009-11-06 Impact factor: 20.096
Authors: Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black Journal: Can Urol Assoc J Date: 2015-10-13 Impact factor: 1.862
Authors: Israt S Alam; Idan Steinberg; Ophir Vermesh; Nynke S van den Berg; Eben L Rosenthal; Gooitzen M van Dam; Vasilis Ntziachristos; Sanjiv S Gambhir; Sophie Hernot; Stephan Rogalla Journal: Mol Imaging Biol Date: 2018-10 Impact factor: 3.488
Authors: Rodolfo Hurle; Paolo Casale; Massimo Lazzeri; Marco Paciotti; Alberto Saita; Piergiuseppe Colombo; Emanuela Morenghi; David Oswald; Daniela Colleselli; Michael Mitterberger; Thomas Kunit; Martina Hager; Thomas R W Herrmann; Lukas Lusuardi Journal: World J Urol Date: 2019-05-21 Impact factor: 4.226
Authors: Kimberley S Samkoe; Brent D Bates; Niki N Tselepidakis; Alisha V DSouza; Jason R Gunn; Dipak B Ramkumar; Keith D Paulsen; Brian W Pogue; Eric R Henderson Journal: J Biomed Opt Date: 2017-12 Impact factor: 3.170